Steppe Cement (STCM)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 39.50 |
|---|---|
| 52-week range | 16.00 – 44.39 |
| Return, 1 month / 3 months | +24.0% / +88.8% |
| Return, 1 year / 3 years | +143.2% / +121.5% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 45.6% |
| Worst drawdown (1 year) | -19.0% |
| Average daily value traded | 6.73M GBX |
| Dividend yield | 8.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Steppe Cement makes and supplies cement from its plant in Kazakhstan, serving construction companies and builders in the domestic market. The company produces clinker and cement for use in housing, infrastructure and commercial building work. Its operations are based in Kazakhstan, where it mines raw materials and runs its own production lines, and its ordinary stock trades on the London market's junior segment.
Steppe Cement trades under the code STCM on the London Stock Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Steppe Cement (STCM) trades on the London Stock Exchange in UK. It last closed at GBX 39.50 on 27 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 227 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 143.2% and over the last three months it rose 88.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 80.4% | ||
| From 52-week high | -10.2% | ||
| Momentum | 98 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 88.8% | ||
| 6-month return | 97.7% | ||
| 12-month return, skipping the last month | 96.2% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 45.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.0% | ||
| Liquidity | 70 · Strong | Trades actively. | |
| Average daily value traded | 6.73M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 52 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 8.9% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.9% |
|---|---|
| 1 month | +24.0% |
| 3 months | +88.8% |
| 6 months | +97.7% |
| 1 year | +143.2% |
| 3 years | +121.5% |
| 5 years | +45.3% |
Signals
| 50-day / 200-day average | 29.24 / 21.89 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.90 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Oct 2026 | GBP 0.0200 |
| 12 Dec 2025 | GBP 0.0150 |
| 18 Dec 2024 | GBP 0.0150 |
| 6 Jun 2024 | GBP 0.0150 |
| 24 May 2024 | GBP 0.0150 |
| 17 Nov 2022 | GBP 0.0500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.